Top Markets
Coin of the day
Regnum Corp. Regnum Corp.

Regnum Corp.

RGMP
Rang in Aktien #42305
Regnum Corp. is dedicated to advancing and marketing therapeutic agents... Regnum Corp. is dedicated to advancing and marketing therapeutic agents designed to combat both rare and infectious diseases. Its flagship product is Leronlimab (PRO 140), a monoclonal antibody functioning as a C-C chemokine receptor type 5 (CCR5) antagonist. This drug is specifically formulated to inhibit the human immunodeficiency virus (HIV) from gaining entry into human cells. Headquartered in New York, New York, Regnum Corp. operates as a subsidiary of Phoenixus AG.
Aktienkurs
$0.0001
Zuletzt synchronisiert: 2026-08-11
Marktkapitalisierung
$2.30K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Regnum Corp. (RGMP)

Kategorie

Kursverlauf für Regnum Corp. (RGMP)
Höchster Schlusskurs: $0.00 am 2026-08-01

Niedrigster Schlusskurs: $0.15 am 2019-05-01
Kursverlauf der Aktie von Regnum Corp. von 2019 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) 0.00%
2025 0.00%
2024 -98.31%
2023 -96.26%
2022 94.68%
2021 -67.77%
2020 114.71%
2019 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$527.87 36.13%
US
$873.57 37.02%
NL
$736.38 8.73%
CH
$263.09 20.45%
BE
$1.07K -5.56%
KR